Ablynx N.V. (ABLYF) Stock Rating Upgraded by Zacks Investment Research

Ablynx N.V. (NASDAQ:ABLYF) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Monday.

According to Zacks, “Ablynx NV is a biopharmaceutical company which engaged in the development of Nanobodies (R) proprietary therapeutic proteins based on single-domain antibody fragments. The company also discovers and develops therapeutic for inflammation, haematology, immuno-oncology, oncology and respiratory disease. Ablynx NV is headquartered in Ghent, Belgium. “

Ablynx N.V. (ABLYF) traded up 1.19% during midday trading on Monday, hitting $15.28. The company had a trading volume of 200 shares. Ablynx N.V. has a 52 week low of $9.10 and a 52 week high of $50.00. The stock has a 50 day moving average price of $14.41 and a 200-day moving average price of $13.01. The stock’s market capitalization is $921.31 million.

COPYRIGHT VIOLATION WARNING: This story was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://www.chaffeybreeze.com/2017/09/18/ablynx-n-v-ablyf-stock-rating-upgraded-by-zacks-investment-research.html.

Receive News & Ratings for Ablynx N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ablynx N.V. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply